Actavis Group hf is scouring emerging markets for a partner to help it copy complicated biotechnology medicines such as Roche Holding AG (ROG)’s $7.7 billion blockbuster Avastin.
The closely held generic-drug maker, based in Zug, Switzerland, is seeking a partner that has already done substantial scientific work to show its versions of biological medicines are safe and effective, Chief Executive Officer Claudio Albrecht said in an interview in Zurich. Actavis is already in talks with some companies, Albrecht said.
